Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation.

Zolpidem is a hypnotic benzodiazepine site agonist with some gamma-aminobutyric acid (GABA)(A) receptor subtype selectivity. Here, we have tested the effects of zolpidem on the hippocampus of gamma2 subunit (gamma2F77I) point mutant mice. Analysis of forebrain GABA(A) receptor expression with immuno...

Full description

Bibliographic Details
Main Authors: Cope, D, Halbsguth, C, Karayannis, T, Wulff, P, Ferraguti, F, Hoeger, H, Leppä, E, Linden, A, Oberto, A, Ogris, W, Korpi, E, Sieghart, W, Somogyi, P, Wisden, W, Capogna, M
Format: Journal article
Language:English
Published: 2005
_version_ 1826305500791177216
author Cope, D
Halbsguth, C
Karayannis, T
Wulff, P
Ferraguti, F
Hoeger, H
Leppä, E
Linden, A
Oberto, A
Ogris, W
Korpi, E
Sieghart, W
Somogyi, P
Wisden, W
Capogna, M
author_facet Cope, D
Halbsguth, C
Karayannis, T
Wulff, P
Ferraguti, F
Hoeger, H
Leppä, E
Linden, A
Oberto, A
Ogris, W
Korpi, E
Sieghart, W
Somogyi, P
Wisden, W
Capogna, M
author_sort Cope, D
collection OXFORD
description Zolpidem is a hypnotic benzodiazepine site agonist with some gamma-aminobutyric acid (GABA)(A) receptor subtype selectivity. Here, we have tested the effects of zolpidem on the hippocampus of gamma2 subunit (gamma2F77I) point mutant mice. Analysis of forebrain GABA(A) receptor expression with immunocytochemistry, quantitative [(3)H]muscimol and [(35)S] t-butylbicyclophosphorothionate (TBPS) autoradiography, membrane binding with [(3)H]flunitrazepam and [(3)H]muscimol, and comparison of miniature inhibitory postsynaptic current (mIPSC) parameters did not reveal any differences between homozygous gamma2I77/I77 and gamma2F77/F77 mice. However, quantitative immunoblot analysis of gamma2I77/I77 hippocampi showed some increased levels of gamma2, alpha1, alpha4 and delta subunits, suggesting that differences between strains may exist in unassembled subunit levels, but not in assembled receptors. Zolpidem (1 microm) enhanced the decay of mIPSCs in CA1 pyramidal cells of control (C57BL/6J, gamma2F77/F77) mice by approximately 60%, and peak amplitude by approximately 20% at 33-34 degrees C in vitro. The actions of zolpidem (100 nm or 1 microm) were substantially reduced in gamma2I77/I77 mice, although residual effects included a 9% increase in decay and 5% decrease in peak amplitude. Similar results were observed in CA1 stratum oriens/alveus interneurons. At network level, the effect of zolpidem (10 microm) on carbachol-induced oscillations in the CA3 area of gamma2I77/I77 mice was significantly different compared with controls. Thus, the gamma2F77I point mutation virtually abolished the actions of zolpidem on GABA(A) receptors in the hippocampus. However, some residual effects of zolpidem may involve receptors that do not contain the gamma2 subunit.
first_indexed 2024-03-07T06:33:47Z
format Journal article
id oxford-uuid:f6ed8fdb-61d4-4ebe-8ef7-b7eee88619b2
institution University of Oxford
language English
last_indexed 2024-03-07T06:33:47Z
publishDate 2005
record_format dspace
spelling oxford-uuid:f6ed8fdb-61d4-4ebe-8ef7-b7eee88619b22022-03-27T12:38:39ZLoss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f6ed8fdb-61d4-4ebe-8ef7-b7eee88619b2EnglishSymplectic Elements at Oxford2005Cope, DHalbsguth, CKarayannis, TWulff, PFerraguti, FHoeger, HLeppä, ELinden, AOberto, AOgris, WKorpi, ESieghart, WSomogyi, PWisden, WCapogna, MZolpidem is a hypnotic benzodiazepine site agonist with some gamma-aminobutyric acid (GABA)(A) receptor subtype selectivity. Here, we have tested the effects of zolpidem on the hippocampus of gamma2 subunit (gamma2F77I) point mutant mice. Analysis of forebrain GABA(A) receptor expression with immunocytochemistry, quantitative [(3)H]muscimol and [(35)S] t-butylbicyclophosphorothionate (TBPS) autoradiography, membrane binding with [(3)H]flunitrazepam and [(3)H]muscimol, and comparison of miniature inhibitory postsynaptic current (mIPSC) parameters did not reveal any differences between homozygous gamma2I77/I77 and gamma2F77/F77 mice. However, quantitative immunoblot analysis of gamma2I77/I77 hippocampi showed some increased levels of gamma2, alpha1, alpha4 and delta subunits, suggesting that differences between strains may exist in unassembled subunit levels, but not in assembled receptors. Zolpidem (1 microm) enhanced the decay of mIPSCs in CA1 pyramidal cells of control (C57BL/6J, gamma2F77/F77) mice by approximately 60%, and peak amplitude by approximately 20% at 33-34 degrees C in vitro. The actions of zolpidem (100 nm or 1 microm) were substantially reduced in gamma2I77/I77 mice, although residual effects included a 9% increase in decay and 5% decrease in peak amplitude. Similar results were observed in CA1 stratum oriens/alveus interneurons. At network level, the effect of zolpidem (10 microm) on carbachol-induced oscillations in the CA3 area of gamma2I77/I77 mice was significantly different compared with controls. Thus, the gamma2F77I point mutation virtually abolished the actions of zolpidem on GABA(A) receptors in the hippocampus. However, some residual effects of zolpidem may involve receptors that do not contain the gamma2 subunit.
spellingShingle Cope, D
Halbsguth, C
Karayannis, T
Wulff, P
Ferraguti, F
Hoeger, H
Leppä, E
Linden, A
Oberto, A
Ogris, W
Korpi, E
Sieghart, W
Somogyi, P
Wisden, W
Capogna, M
Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation.
title Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation.
title_full Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation.
title_fullStr Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation.
title_full_unstemmed Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation.
title_short Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation.
title_sort loss of zolpidem efficacy in the hippocampus of mice with the gabaa receptor gamma2 f77i point mutation
work_keys_str_mv AT coped lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT halbsguthc lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT karayannist lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT wulffp lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT ferragutif lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT hoegerh lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT leppae lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT lindena lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT obertoa lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT ogrisw lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT korpie lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT sieghartw lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT somogyip lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT wisdenw lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation
AT capognam lossofzolpidemefficacyinthehippocampusofmicewiththegabaareceptorgamma2f77ipointmutation